Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 5/20 | 0.35 |
| ▸ | NPY1R | P25929 | 3/20 | 0.35 |
| ▸ | NPY2R | P49146 | 3/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724846 | 1.00 | FOLH1 (0.40) | FOLH1C3AR1MEN1GAAKMT2A | |
| SCHEMBL31184339 | 0.90 | FOLH1 (0.39) | FOLH1C3AR1MEN1GAAKMT2A | |
| SCHEMBL24805405 | 0.88 | C3AR1 (0.48) | FOLH1C3AR1MEN1GAAKMT2A | |
| SCHEMBL20275937 | 0.87 | NOD1 (0.38) | FOLH1C3AR1MEN1GAAKMT2A | |
| SCHEMBL18464241 | 0.86 | NPY4R (0.42) | FOLH1MEN1GAAKMT2AGRIA1 | |
| SCHEMBL1070697 | 0.85 | ALDH1A1 (0.41) | FOLH1C3AR1MEN1KMT2ANOD1 | |
| SCHEMBL1070699 | 0.85 | ALDH1A1 (0.41) | FOLH1C3AR1MEN1KMT2ANOD1 | |
| SCHEMBL29005731 | 0.84 | C3AR1 (0.43) | FOLH1C3AR1MEN1KMT2ANOD1 | |
| SCHEMBL12971304 | 0.84 | C3AR1 (0.43) | FOLH1C3AR1MEN1KMT2ANOD1 | |
| SCHEMBL16589746 | 0.83 | GRIA1 (0.45) | GRIA1NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3272764-B1 | METHOD FOR AFFINITY CHROMATOGRAPHY | NOVARTIS AG (CH) | 2024-02-07 | — | — | EP | claimed |
| EP-2059258-B1 | ARGININE WASH IN PROTEIN PURIFICATION USING AFFINITY CHROMATOGRAPHY | WYETH LLC (US) | 2019-11-13 | — | — | EP | claimed |
| EP-2714714-B1 | WASH SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY | NOVARTIS AG (CH) | 2018-06-20 | — | — | EP | claimed |
| EP-2513134-B1 | WASH SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY | NOVARTIS AG (CH) | 2017-09-06 | — | — | EP | claimed |
| EP-1568710-A2 | Antibody purification method | Ajinomoto Co., Inc. (JP) | 2005-08-31 | — | — | EP | claimed |
| EP-3272764-B1 | METHOD FOR AFFINITY CHROMATOGRAPHY | NOVARTIS AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022266753-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-12-29 | — | — | WO | disclosed |
| US-10913972-B2 | 5,5-disubstituted luciferins and their use in luciferase-based assays | PROMEGA CORPORATION (US) | 2021-02-09 | — | — | US | disclosed |
| US-10400264-B2 | 5,5-disubstituted luciferins and their use in luciferase-based assays | PROMEGA CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180155762-A1 | 5,5-DISUBSTITUTED LUCIFERINS AND THEIR USE IN LUCIFERASE-BASED ASSAYS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| US-20180155762-A1 | 5,5-DISUBSTITUTED LUCIFERINS AND THEIR USE IN LUCIFERASE-BASED ASSAYS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| EP-2513134-B1 | WASH SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY | NOVARTIS AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-20100304273-A1 | PROTON CONDUCTING MEMBRANES FOR FUEL CELLS HAVING A PROTON GRADIENT AND METHODS FOR PREPARING SAID MEMBRANES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-12-02 | — | — | US | disclosed |
| EP-1568710-B1 | Antibody purification method | AJINOMOTO KK (JP) | 2009-12-23 | — | — | EP | disclosed |
| EP-1568710-A2 | Antibody purification method | Ajinomoto Co., Inc. (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155762-A1 | 5,5-DISUBSTITUTED LUCIFERINS AND THEIR USE IN LUCIFERASE-BASED ASSAYS | GLB1, LUC7L2, GUSB | FOLH1 449/4885C3AR1 4674/4885MEN1 2121/4885 |
| US-10400264-B2 | 5,5-disubstituted luciferins and their use in luciferase-based assays | GLB1, GUSB, LUC7L2 | FOLH1 500/4885C3AR1 4698/4885MEN1 2128/4885 |
| US-10913972-B2 | 5,5-disubstituted luciferins and their use in luciferase-based assays | GLB1, LUC7L2, GUSB | FOLH1 449/4885C3AR1 4674/4885MEN1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.